GlobeNewswire05.02.19
B. Braun Medical Inc. and Nexus Medical, LLC announced today that they have entered into a long-term distribution agreement for the TKO-6P (power injectable) Luer Activated Anti-Reflux Device.
“The TKO-6P Luer Activated Anti-Reflux Device is designed to deliver IV catheter patency,” said Steve Weber, Director of Marketing – IV Systems & Vascular Access at B. Braun. “This agreement will complement B. Braun’s current needleless connector portfolio offering to include an anti-reflux line of products,” added Steve.
The TKO-6P Luer Activated Anti-Reflux Device is designed to provide 24/7 IV catheter patency which is vital to the administration of medications and fluids. The Nexus TKO technology is an anti-reflux device available with proven results demonstrating a decrease in occlusion rates when heparin flushes were eliminated.1
“It is our mission to eliminate preventable catheter occlusions that cause unnecessary harm and delays as well as increased costs in patient treatment,” said Cary Dikeman, Chairman and President of Nexus Medical, LLC. “Together with B. Braun, we can make a significant impact to patient care and expand our customer coverage,” said Cary.
Reference
1 Jansinky, L. et al. (2009), Occlusion reduction and heparin elimination trial using an antireflux device on peripheral and central venous catheters.
“The TKO-6P Luer Activated Anti-Reflux Device is designed to deliver IV catheter patency,” said Steve Weber, Director of Marketing – IV Systems & Vascular Access at B. Braun. “This agreement will complement B. Braun’s current needleless connector portfolio offering to include an anti-reflux line of products,” added Steve.
The TKO-6P Luer Activated Anti-Reflux Device is designed to provide 24/7 IV catheter patency which is vital to the administration of medications and fluids. The Nexus TKO technology is an anti-reflux device available with proven results demonstrating a decrease in occlusion rates when heparin flushes were eliminated.1
“It is our mission to eliminate preventable catheter occlusions that cause unnecessary harm and delays as well as increased costs in patient treatment,” said Cary Dikeman, Chairman and President of Nexus Medical, LLC. “Together with B. Braun, we can make a significant impact to patient care and expand our customer coverage,” said Cary.
Reference
1 Jansinky, L. et al. (2009), Occlusion reduction and heparin elimination trial using an antireflux device on peripheral and central venous catheters.